acnatac 10 mg/g + 0,25 mg/g
meda pharma gmbh & co. kg - germania - combinatii (clindamycinum+tretinoinum) - gel - 10mg/g+0,25mg/g - preparate pt. trat. acneei de uz topic antiinfectioase pentru tratamentul acneei
acnatac 10 mg/g + 0,25 mg/g
meda pharma gmbh & co. kg - germania - combinatii (clindamycinum+tretinoinum) - gel - 10mg/g+0,25mg/g - preparate pt. trat. acneei de uz topic antiinfectioase pentru tratamentul acneei
duodopa 20 mg/ml+5 mg/ml
fresenius kabi norge as - norvegia - combinatii (levodopum+carbidopum) - gel intestinal - 20mg/ml+5mg/ml - medicamente dopaminergice dopa si derivati
dexagel 0,985 mg/g
dr. gerhard mann chem-pharm. fabrik gmbh - germania - dexamethasonum - gel oft. - 0,985 mg/g - antiinflamatoare corticosteroizi
sutent
pfizer limited - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sutent is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib mesilate treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sutent is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sutent is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours with disease progression in adults. experience with sutent as first-line treatment is limited (see section 5.
prozinc
boehringer ingelheim vetmedica gmbh - insulin human - insuline și analogi injectabili, cu acțiune intermediară - cats; dogs - pentru tratamentul diabetului zaharat la pisici și câini pentru a realiza reducerea hiperglicemiei și îmbunătățirea unor semne clinice asociate.
sunitinib accord
accord healthcare s.l.u. - sunitinib - gastrointestinal stromal tumors; carcinoma, renal cell; neuroendocrine tumors - agenți antineoplazici - gastrointestinal stromal tumour (gist)sunitinib accord is indicated for the treatment of unresectable and/or metastatic malignant gastrointestinal stromal tumour (gist) in adults after failure of imatinib treatment due to resistance or intolerance. metastatic renal cell carcinoma (mrcc)sunitinib accord is indicated for the treatment of advanced/metastatic renal cell carcinoma (mrcc) in adults. pancreatic neuroendocrine tumours (pnet)sunitinib accord is indicated for the treatment of unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumours (pnet) with disease progression in adults.
mirapex er comprimate cu eliberare prelungita 0,375 mg
boehringer ingelheim international gmbh - olanzapinum - comprimate cu eliberare prelungita - 0,375 mg
mirapex er comprimate cu eliberare prelungita 0,75 mg
boehringer ingelheim international gmbh - olanzapinum - comprimate cu eliberare prelungita - 0,75 mg
mirapex er comprimate cu eliberare prelungita 1,5 mg
boehringer ingelheim international gmbh - olanzapinum - comprimate cu eliberare prelungita - 1,5 mg